Post by Anne-Sophie van den Heerik

✨ Happy to share a milestone! ✨ I don’t usually post personal highlights here on LinkedIn — but today feels like an exception. Proud to share that the results of the PORTEC-4a trial have been published in The Lancet Oncology! PORTEC-4a is a large international phase III study evaluating whether molecular profile-based adjuvant treatment can safely guide radiotherapy decisions for women with high-intermediate risk endometrial cancer Key takeaways from the study: • Adjuvant treatment guided by tumour molecular profiling was non-inferior to standard adjuvant vaginal brachytherapy in patients with high-intermediate risk endometrial cancer. • Nearly half (46%) of patients in the molecular profile-guided arm with a favourable molecular profile were able to safely avoid adjuvant vaginal brachytherapy without compromising outcomes. • For women with an unfavourable molecular profile, indicating a higher risk of disease recurrence, pelvic radiotherapy instead of vaginal brachytherapy was associated with improved locoregional control This work represents a truly collaborative international effort, and I am very thankful to all collaborators, and especially my co-authors Nanda Horeweg Dorien Haverkort Nienke Kuijsters Stefan Kommoss Friderike Koppe Marlies Nowee Henrike Westerveld Marianne de Jong Filip Fruhauf Jeltsje C. Jan Willem Mens Jannet Beukema Cyrus Chargari Charles Gillham Ina Jurgenliemk-Schulz Katrien Vandecasteele Dr. med. Moritz Hamann Mandy Kiderlen Annette Staebler Hans W. Nijman Bastiaan Wortman Eleftheria A. Stephanie de Boer Wilbert van den Hout Karen Verhoeven-Adema Remi Nout Hein Putter Tjalling Bosse and Carien Creutzberg. For those interested, the full article can be read here: https://lnkd.in/eFh-YHva #PORTEC4a #EndometrialCancer #Brachytherapy #AdjuvantTreatment #GynaecologicalCancer #RadiationOncology #LancetOncology